Beta Bionics Statistics
Total Valuation
Beta Bionics has a market cap or net worth of $450.52 million. The enterprise value is $257.91 million.
Important Dates
The last earnings date was Tuesday, April 21, 2026, after market close.
| Earnings Date | Apr 21, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Beta Bionics has 44.56 million shares outstanding. The number of shares has increased by 250.60% in one year.
| Current Share Class | 44.56M |
| Shares Outstanding | 44.56M |
| Shares Change (YoY) | +250.60% |
| Shares Change (QoQ) | +0.55% |
| Owned by Insiders (%) | 5.46% |
| Owned by Institutions (%) | 80.24% |
| Float | 25.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.09 |
| Forward PS | 3.08 |
| PB Ratio | 1.66 |
| P/TBV Ratio | 1.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.69, with a Debt / Equity ratio of 0.03.
| Current Ratio | 10.69 |
| Quick Ratio | 9.39 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -22.71% and return on invested capital (ROIC) is -16.14%.
| Return on Equity (ROE) | -22.71% |
| Return on Assets (ROA) | -15.04% |
| Return on Invested Capital (ROIC) | -16.14% |
| Return on Capital Employed (ROCE) | -27.49% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $260,610 |
| Profits Per Employee | -$157,066 |
| Employee Count | 423 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 2.39 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.05% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -33.05% |
| 50-Day Moving Average | 10.56 |
| 200-Day Moving Average | 18.81 |
| Relative Strength Index (RSI) | 48.20 |
| Average Volume (20 Days) | 732,635 |
Short Selling Information
The latest short interest is 6.19 million, so 13.90% of the outstanding shares have been sold short.
| Short Interest | 6.19M |
| Short Previous Month | 7.14M |
| Short % of Shares Out | 13.90% |
| Short % of Float | 24.41% |
| Short Ratio (days to cover) | 5.09 |
Income Statement
In the last 12 months, Beta Bionics had revenue of $110.24 million and -$66.44 million in losses. Loss per share was -$1.51.
| Revenue | 110.24M |
| Gross Profit | 63.00M |
| Operating Income | -77.31M |
| Pretax Income | -66.44M |
| Net Income | -66.44M |
| EBITDA | -75.46M |
| EBIT | -77.31M |
| Loss Per Share | -$1.51 |
Full Income StatementBalance Sheet
The company has $199.52 million in cash and $6.91 million in debt, with a net cash position of $192.61 million or $4.32 per share.
| Cash & Cash Equivalents | 199.52M |
| Total Debt | 6.91M |
| Net Cash | 192.61M |
| Net Cash Per Share | $4.32 |
| Equity (Book Value) | 271.25M |
| Book Value Per Share | 6.09 |
| Working Capital | 224.80M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$54.78 million and capital expenditures -$6.34 million, giving a free cash flow of -$61.12 million.
| Operating Cash Flow | -54.78M |
| Capital Expenditures | -6.34M |
| Depreciation & Amortization | 1.86M |
| Net Borrowing | n/a |
| Free Cash Flow | -61.12M |
| FCF Per Share | -$1.37 |
Full Cash Flow StatementMargins
Gross margin is 57.15%, with operating and profit margins of -70.13% and -60.27%.
| Gross Margin | 57.15% |
| Operating Margin | -70.13% |
| Pretax Margin | -60.27% |
| Profit Margin | -60.27% |
| EBITDA Margin | -68.45% |
| EBIT Margin | -70.13% |
| FCF Margin | n/a |
Dividends & Yields
Beta Bionics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -250.60% |
| Shareholder Yield | -250.60% |
| Earnings Yield | -14.75% |
| FCF Yield | -13.57% |
Analyst Forecast
The average price target for Beta Bionics is $19.18, which is 89.71% higher than the current price. The consensus rating is "Buy".
| Price Target | $19.18 |
| Price Target Difference | 89.71% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 30.16% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Beta Bionics has an Altman Z-Score of 13.15 and a Piotroski F-Score of 2.
| Altman Z-Score | 13.15 |
| Piotroski F-Score | 2 |
